KRAS and adenocarcinoma: A549 represents a well-validated adenocarcinoma model harboring characteristic KRAS mutations and, critically, exhibits dysregulated iron metabolism-a pathophysiological feature essential for DHA bioactivation that mirrors clinical NSCLC profiles (Zheng et al., 2023; Ba et al., 2012).